JP2015083580A5 - - Google Patents

Download PDF

Info

Publication number
JP2015083580A5
JP2015083580A5 JP2014245645A JP2014245645A JP2015083580A5 JP 2015083580 A5 JP2015083580 A5 JP 2015083580A5 JP 2014245645 A JP2014245645 A JP 2014245645A JP 2014245645 A JP2014245645 A JP 2014245645A JP 2015083580 A5 JP2015083580 A5 JP 2015083580A5
Authority
JP
Japan
Prior art keywords
constipation
pharmaceutical
medicament
functional
glucopyranosyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014245645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015083580A (ja
JP6105546B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2014245645A priority Critical patent/JP6105546B2/ja
Priority claimed from JP2014245645A external-priority patent/JP6105546B2/ja
Publication of JP2015083580A publication Critical patent/JP2015083580A/ja
Publication of JP2015083580A5 publication Critical patent/JP2015083580A5/ja
Application granted granted Critical
Publication of JP6105546B2 publication Critical patent/JP6105546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014245645A 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途 Active JP6105546B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014245645A JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012105847 2012-05-07
JP2012105847 2012-05-07
JP2014245645A JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014514708A Division JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2015083580A JP2015083580A (ja) 2015-04-30
JP2015083580A5 true JP2015083580A5 (https=) 2016-06-16
JP6105546B2 JP6105546B2 (ja) 2017-03-29

Family

ID=49550709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014514708A Active JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途
JP2014245645A Active JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014514708A Active JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Country Status (15)

Country Link
US (2) US9273085B2 (https=)
EP (1) EP2848254B1 (https=)
JP (2) JP5663699B2 (https=)
KR (1) KR101868991B1 (https=)
CN (1) CN104284665B (https=)
AU (1) AU2013258566B2 (https=)
BR (1) BR112014027841B1 (https=)
CA (1) CA2872002C (https=)
DK (1) DK2848254T3 (https=)
ES (1) ES2601127T3 (https=)
MX (1) MX359988B (https=)
PL (1) PL2848254T3 (https=)
PT (1) PT2848254T (https=)
RU (1) RU2602739C2 (https=)
WO (1) WO2013168671A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3400944T3 (pl) 2010-11-04 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
CA2872002C (en) * 2012-05-07 2019-01-15 Masayuki Isaji Pyrazole derivative and use thereof for medical purposes
EP2952206B1 (en) 2013-02-04 2018-10-24 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic drug for constipation
CN106573033A (zh) * 2014-06-25 2017-04-19 Ea制药株式会社 固体制剂及其稳定化方法
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
CA3094118A1 (en) 2018-03-28 2019-10-03 Avolynt Method for treating post-prandial hypoglycemia
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
BR112020024479A2 (pt) 2018-06-20 2021-03-02 Albireo Ab hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
HUE060905T2 (hu) 2019-02-06 2023-04-28 Albireo Ab Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
ES2973549T3 (es) 2019-12-04 2024-06-20 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
CN101511840A (zh) * 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
EP2228378B1 (en) * 2007-12-27 2015-09-09 Kissei Pharmaceutical Co., Ltd. Monosebacate of pyrazole derivative
EP2275430B1 (en) 2008-04-16 2012-05-16 Kissei Pharmaceutical Co., Ltd. Hemifumarate of a pyrazole derivative
TW201105336A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Combined medicine of pyrazole derivative and biguanide drug
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
CA2872002C (en) * 2012-05-07 2019-01-15 Masayuki Isaji Pyrazole derivative and use thereof for medical purposes

Similar Documents

Publication Publication Date Title
JP2015083580A5 (https=)
ES2601127T3 (es) Derivado de pirazol y su uso con fines médicos
JP2015523407A5 (https=)
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
JP2015057451A5 (https=)
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
JP2016106150A5 (https=)
JP2012193216A5 (https=)
JP2017506624A5 (https=)
JP2014198723A5 (https=)
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
CN111836807A (zh) 氧杂螺环类化合物及其制备方法和用途
JP2018537507A5 (https=)
JP2017014206A5 (https=)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2013166781A5 (https=)
JP2019518022A5 (https=)
JP2018521007A5 (https=)
JP2018531273A5 (https=)
JP2019218379A5 (https=)
JP2016540000A5 (https=)
JP2016538288A5 (https=)
JP2013032308A5 (https=)
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.